Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VB5-845D-800CW is an investigational near-infrared (NIR) fluorescent imaging agent designed for intraoperative fluorescence-guided surgery. It consists of a Fab-fragment antibody (derived from the VB6-845 series) that specifically targets the epithelial cell adhesion molecule (EpCAM), conjugated to the NIR fluorescent dye IRDye800CW. EpCAM is highly overexpressed in various epithelial malignancies, including colorectal, oesophageal, and gastric cancers. By binding to tumor cells, the agent allows surgeons to visualize tumor margins and detect occult lesions in real-time using NIR imaging systems. It is currently being evaluated in Phase I clinical trials for the detection of gastrointestinal cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VB5-845D-800CW.